Compare SAR & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAR | CABA |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.3M | 319.6M |
| IPO Year | N/A | 2019 |
| Metric | SAR | CABA |
|---|---|---|
| Price | $22.05 | $3.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $23.75 | $14.50 |
| AVG Volume (30 Days) | 98.2K | ★ 4.3M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 14.34% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.39 | N/A |
| P/E Ratio | $9.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.78 | $1.26 |
| 52 Week High | $25.64 | $4.23 |
| Indicator | SAR | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 42.73 | 48.38 |
| Support Level | $21.40 | $2.17 |
| Resistance Level | $23.74 | $3.54 |
| Average True Range (ATR) | 0.43 | 0.34 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 6.51 | 39.93 |
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.